发明名称 |
Y-90-LABELED ANTI-CD22 ANTIBODY (EPRATUZUMAB TETRAXETAN) IN REFRACTORY/RELAPSED ADULT CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA |
摘要 |
The present invention relates to use of 90Y-conjugated anti-CD22 antibody for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Preferably the anti-CD22 antibody is epratuzumab tetraxetan. More preferably, the radiolabeled antibody is administered at a dosage of between 2.5 and 10.0 mCi/m2, most preferably on days 1 and 8 of the cycle. In specific embodiments, the dosage may be 2.5, 5.0, 7.5 or 10.0 mCi/m2. The radiolabeled antibody is capable of inducing a complete response in individuals with relapsed/refractory ALL. |
申请公布号 |
US2016296648(A1) |
申请公布日期 |
2016.10.13 |
申请号 |
US201615088491 |
申请日期 |
2016.04.01 |
申请人 |
Immunomedics, Inc. ;CHU de Nantes ;INSERM ;University of Nantes |
发明人 |
Chevallier Patrice;Kraeber-Bodere Francoise;Goldenberg David M. |
分类号 |
A61K51/10;C07K16/28 |
主分类号 |
A61K51/10 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating refractory and/or relapsed B-cell acute lymphoblastic leukemia (ALL), comprising administering to a patient with refractory/relapsed B-cell ALL a 90Y-labeled anti-CD22 antibody. |
地址 |
Morris Plains NJ US |